CENBF (CEN Biotech) LT-Debt-to-Total-Asset: 0.02 (As of Mar. 2023)


What is CEN Biotech LT-Debt-to-Total-Asset?

CEN Biotech CENBF LT-Debt-to-Total-Asset is 0.02 as of Mar. 2023.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. CEN Biotech's long-term debt to total assests ratio for the quarter that ended in Mar. 2023 was 0.02.

CEN Biotech's long-term debt to total assets ratio declined from Mar. 2022 (0.03) to Mar. 2023 (0.02). It may suggest that CEN Biotech is progressively becoming less dependent on debt to grow their business.

CEN Biotech  (OTCPK:CENBF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

CEN Biotech LT-Debt-to-Total-Asset Related Terms

CEN Biotech LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for CEN Biotech's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CEN Biotech LT-Debt-to-Total-Asset Chart

CEN Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only 0.43 0.17 0.04 0.03 0.02

CEN Biotech Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.02 0.02 0.02

CEN Biotech LT-Debt-to-Total-Asset Calculation

CEN Biotech's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )/Total Assets (A: Dec. 2022 )
=0.177/7.859
=0.02

CEN Biotech's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2023 is calculated as

LT Debt to Total Assets (Q: Mar. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2023 )/Total Assets (Q: Mar. 2023 )
=0.131/7.447
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.02 mean?
CEN Biotech (CENBF) has a LT-Debt-to-Total-Asset of 0.02 as of Mar. 2023. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on CEN Biotech and its competitors.
Is CEN Biotech's LT-Debt-to-Total-Asset too high?
CEN Biotech's current LT-Debt-to-Total-Asset is 0.02.
How does CEN Biotech's LT-Debt-to-Total-Asset compare to INLB and NEPT?
CEN Biotech's LT-Debt-to-Total-Asset of 0.02 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on CEN Biotech and its competitors. CEN Biotech's current LT-Debt-to-Total-Asset is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CEN Biotech stock overvalued right now?
CEN Biotech (CENBF) has a current LT-Debt-to-Total-Asset of 0.02. The current LT-Debt-to-Total-Asset is 0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For CEN Biotech (CENBF), the current LT-Debt-to-Total-Asset is 0.02 as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CEN Biotech Business Description

Address 3295 Quality Way, Suite 300, Windsor, ON, CAN, N8T 3R9
CEN Biotech Inc is an early-stage Canadian biopharmaceutical company. The Company grows, sells, and delivers pharmaceutical-grade medical marijuana to patients.